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As soon as a patient is diagnosed with chronic
hepatitis C, preparations can begin for treatment
with direct-acting antivirals (DAAs). Most patients
can receive DAA therapy in general practice.
GPs are ideally placed to assess their patients in
preparation for DAA therapy and to identify
the minority who require specialist referral.

W

ith the introduction of direct-acting antivirals
(DAAs) in Australia in 2016, most people with
chronic hepatitis C can be cured of this infection.
GPs and suitably qualified nurse practitioners
working in all areas of primary care have a key role in identifying,
testing and treating their patients with hepatitis C.
The previous article in this series discussed how to identify
your patients with hepatitis C. This article provides practical
advice on assessing a patient after diagnosis in preparation for
DAA therapy. This includes determining whether they can be
safely treated in general practice or require specialist referral.
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KEY POINTS
• Most patients with hepatitis C can be treated with directacting antivirals (DAAs) in general practice.

• GPs are ideally placed to assess patients in preparation
for DAA therapy.

• Pretreatment assessment includes a comprehensive
medical and social history, medication review, physical
examination and investigations.
• Key questions to determine the safety of DAA therapy in
primary care concern the presence of cirrhosis, hepatitis C
virus (HCV) genotype, hepatitis B or HIV coinfection,
potential drug interactions, previous HCV treatment and
renal function.
• Patients with cirrhosis, complex comorbidities or who
have previously failed DAA therapy should be referred for
specialist care.

Monash University, Melbourne, Vic.
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1. PRETREATMENT ASSESSMENT OF PEOPLE WITH CHRONIC HEPATITIS C VIRUS
(HCV) INFECTION1*
History
• Estimated duration of HCV infection
• Previous HCV treatment: date, regimen and response
• Cofactors for liver disease progression: alcohol intake, marijuana use, virological
cofactors (HIV, hepatitis B virus), diabetes, obesity
• If ribavirin treatment is planned then note any history of ischaemic heart disease or
cardiovascular risk factors
• Vaccinations against hepatitis A and B viruses
• Physical and psychiatric comorbidities
• Ongoing risk factors for viral transmission and reinfection
• Social issues, potential barriers to medication adherence
Medication

After diagnosis, what next?
All people diagnosed with hepatitis C
should be considered for DAA therapy.
DAAs have the potential to cure most
people with hepatitis C and have few
contraindications. As soon as a patient is
diagnosed with hepatitis C, assessment for
treatment can begin, in consultation with
the patient.
Pretreatment assessment
Patient assessment in preparation for treatment includes:
• comprehensive medical and social
histories
• medication review
• physical examination
• investigations, including a liver
fibrosis assessment.
A full list of the required assessments
and investigations appears in Box 1.1
Six key questions need to be answered
to help determine whether the patient can
be treated safely in primary care or needs
to be referred to a specialist, and the most
appropriate treatment option. These
questions regard the individual, the
hepatitis C virus (HCV) and the liver.
The key questions are:2
• Does the patient have cirrhosis?
• What is the genotype of the
infecting HCV? (This requirement
may be removed in the future owing
to the availability of pangenotypic
agents.)

• Concomitant medications (prescription, over the counter, illicit)
Physical examination
• Features of cirrhosis: hard liver edge, spider naevi, leukonychia
• Features of decompensation or portal hypertension: jaundice, ascites, oedema,
bruising, muscle wasting, encephalopathy
• Body weight and body mass index
Virology
• HCV RNA PCR testing
• HCV genotype†
• Consider HCV RNA level (quantitative)‡
• Hepatitis B virus serology (HBsAg, anti-HBc, anti-HBs§), HIV, hepatitis A serology
Investigations
• Full blood examination, liver function tests, urea and electrolytes, eGFR, INR
• Pregnancy test for women with childbearing potential
• Liver fibrosis assessment, for example
–– transient elastography (e.g. FibroScan), shear wave elastography or acoustic
radiation force impulse (ARFI) imaging
–– serum biomarker (APRI, Hepascore, ELF test, FibroGENE¶)
• Liver ultrasound examination should be performed in people with cirrhosis to
exclude hepatocellular carcinoma (within three months before starting DAAs)
• ECG should be performed if ribavirin therapy is planned and patient is over 50 years
of age or has cardiac risk factors
Abbreviations: anti-HBc = hepatitis B core antibody; anti-HBs = hepatitis B surface antibody;
APRI = aspartate aminotransferase to platelet ratio index; DAA = direct-acting antiviral;
eGFR = estimated glomerular filtration rate; ELF = enhanced liver fibrosis; HBsAg = hepatitis B surface antigen;
INR = international normalised ratio.
* Adapted from Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for
the management of hepatitis C virus infection: a consensus statement (September 2018). Melbourne:
Gastroenterological Society of Australia; 2018 (www.asid.net.au/documents/item/1208).1
†

HCV genotyping is a PBS criterion; it is important before prescribing elbasvir plus grazoprevir or sofosbuvir plus
ledipasvir.

‡

HCV RNA level is important for determining eligibility for eight-week treatment duration with sofosbuvir plus
ledipasvir.

§

All three tests for hepatitis B virus may be requested if the clinical notes indicate acute or chronic hepatitis.

¶

FibroGENE is a gene-based model for staging liver fibrosis; a FibroGENE calculator is available online
(www.fibrogene.com/viral_hepatitis.html).
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Eliminating Hepatitis C: Assessing your patient continued

PATHWAYS TO LIVER FIBROSIS ASSESSMENT IN PRIMARY CARE
FOR PATIENTS WITH HEPATITIS C2*

Patient confirmed with chronic hepatitis C (PCR positive)

Initial liver fibrosis assessment using APRI score†

APRI <1.0

APRI ≥1.0

Patient needs FibroScan
to exclude cirrhosis

If patient is suitable,
perform FibroScan‡

FibroScan reading
<12.5 kPA

No cirrhosis
Patient suitable for HCV
treatment in primary care

If patient is not suitable
for FibroScan,‡ refer to
specialist §

FibroScan reading
≥12.5 kPA

Likely cirrhosis
Refer to specialist for
assessment and treatment §

vaccinations are subsidised for patients
with liver disease and those who are
at high risk of infection in some
jurisdictions.

Liver fibrosis assessment
Liver fibrosis assessment is important to
determine whether the patient has c irrhosis
(Flowchart).2 Although all patients are
eligible for treatment, regardless of their
cirrhosis status, the presence of cirrhosis
determines the need for referral for
specialist care and influences treatment
regimen and duration in some cases, as
well as follow up after treatment.1 Most
patients do not have advanced liver disease
and can be treated easily in primary care.
The two most widely used noninvasive
methods for assessing liver fibrosis are:
• the aspartate aminotransferase
(AST) to platelet ratio index (APRI)
• transient elastography, including
FibroScan.

Current active injecting
drug use is not a contraindication
to hepatitis C treatment

Abbreviations: APRI = aspartate aminotransferase to platelet ratio index; PCR = polymerase chain reaction.
* Adapted from Burnet Institute Eliminate Hepatitis C Partnership. Eliminate hepatitis C partnership practice
support toolkit. Melbourne: Burnet Institute; 2018 (https://ecpartnership.org.au/toolkit). 2
An APRI calculator is available at: www.hepatitisc.uw.edu/page/clinical-calculators/apri

†

‡

FibroScan is not approved for use in people younger than 18 years, pregnant women, people with ascites
and people with a pacemaker or implantable defibrillator. FibroScan and APRI results should be interpreted in
conjunction with a full clinical picture by a trained clinician.
§
Appropriate specialists include gastroenterologists, hepatologists and infectious disease physicians,
depending on local referral processes.

• Is the patient coinfected with HIV or
hepatitis B virus (HBV)?
• Are there any potential drug
interactions between the patient’s
current medication and the DAAs?
• Has the patient previously been
treated for hepatitis C?
• What is the patient’s renal function?
An important part of the pretreatment
assessment is determining the presence
of advanced liver disease. Patients with
cirrhosis require specialist referral and
may need changes to the standard treatment regimen.
12 MedicineToday
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It is also important to address potential psychosocial barriers to treatment
during the assessment process. Current
active injecting drug use is not a contraindication to hepatitis C treatment.
However, some patients may need support to stabilise drug and alcohol use or
to establish adherence support services
before treatment.
Vaccinations
All susceptible patients with hepatitis C
should be offered vaccinations against
hepatitis A and B viruses. These

AST to platelet ratio index
The APRI has been developed as a simple
serum biomarker for assessing fibrosis
using results from a full blood count and
liver function test. The APRI is calculated
from the AST level and platelet count.
APRI calculators are readily available
online (e.g. www.hepatitisc.uw.edu/page/
clinical-calculators/apri). Alternatively,
the APRI can be calculated using the
formula shown in the Figure. An APRI
result of 1.0 or more indicates possible
cirrhosis; the patient should be referred
for further assessment including transient
elastography. An APRI result less than
1.0 suggests that cirrhosis is unlikely and
further evaluation for cirrhosis is usually
not necessary unless clinically indicated;
the patient can proceed on the treatment
pathway.
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2. RISK FACTORS FOR CIRRHOSIS
AND SIGNS OF ADVANCED LIVER
DISEASE

÷
X

Clinical risk factors for cirrhosis1
• Male sex
• Older age when infected
• More than 20 years of HCV infection

Figure. Formula for the aspartate aminotransferase (AST) to platelet ratio index (APRI).

• Comorbidities including:
–– diabetes
–– metabolic syndrome

Transient elastography
Transient elastography measures the
stiffness of the liver, which is used to
assess liver fibrosis. Threshold levels can
determine the presence of cirrhosis. FibroScan is the most extensively validated and
widely available method of transient
elastography. It uses a series of short,
pulsed, low-frequency sound waves and
is similar to an abdominal ultrasound
examination in terms of patient experience.
FibroScan takes a trained operator (usually
a nurse or doctor) 10 to 15 minutes to perform. GPs can refer patients to a liver clinic
for a FibroScan. In some areas, specialist
hepatology nurses offer FibroScan clinics
in the community.
A FibroScan reading of 12.5 kPa or
higher indicates a high likelihood of
cirrhosis.3 The patient requires referral to
a specialist for management and regular
monitoring for complications of cirrhosis,
including hepatocellular carcinoma.
Patients with a FibroScan result of less
than 12.5 kPa are generally suitable for
DAA therapy in primary care.

methods are convenient but less well
validated in identifying fibrosis in the
presence of chronic hepatitis C.1

Drug interactions
DAAs can interact with many medications. Common examples include proton
pump inhibitors, statins, ethinylestradiol
and antiepileptic m
 edications such as
carbamazepine and phenytoin. The
potential for interactions depends on the
specific DAA. The University of Liverpool
in the UK has developed a comprehensive
tool for checking potential drug inter
actions (available online at: www.hepdruginteractions.org).

diseases physicians and sexual health
physicians, depending on the indication
for the referral and local pathway (including telehealth or other videoconferencing
consultations for GPs and patients in
rural or remote areas who have limited
access to specialist care).

A FibroScan reading of
12.5 kPa or higher indicates a high
likelihood of cirrhosis. The patient
requires referral to a specialist

When to refer
Most patients with hepatitis C can
receive DAA therapy safely in primary
care (see the case study in Box 3 and the
Table). Patients with cirrhosis, complex
comorbidities or who have received
previous failed DAA therapy should be
referred for specialist care (Box 4).1,2
Appropriate specialists are those who
have expertise in treating patients with
viral hepatitis. This includes gastro
enterologists, hepatologists, infectious

Psychosocial assessment
When determining patient readiness for
DAA therapy, GPs must take account
of comorbidities, lifestyle and social
issues. Major psychiatric disorders such
as schizophrenia or ongoing drug use
(including injecting drug use) and alcohol
use or being homeless can pose challenges to adherence for patients but are
not contraindications to treatment. It is
important to optimise the patient’s health
when they are considering treatment.

Alternative methods for evaluating
liver stiffness are offered by some radiology services as an add-on to a liver ultrasound examination. They include shear
wave elastography and acoustic radiation
force impulse (ARFI) imaging. These

Risk factors and signs of cirrhosis
Other clinical information should be
collected to determine a patient’s risk of
cirrhosis. This includes their clinical risk
factors for cirrhosis and signs of advanced
liver disease on physical examination
(Box 2). A comprehensive patient assessment is needed because the APRI and
FibroScan may not detect cirrhosis in all
patients.

–– coinfection with hepatitis B virus
or HIV
–– obesity
–– excessive alcohol consumption
Physical signs of advanced liver
disease
• Leukonychia
• Spider naevi
• Palmar erythema
• Gynaecomastia
• Hepatic flap
• Foetor
• Splenomegaly or hepatomegaly
• Oedema
• Ascites
• Jaundice
• Encephalopathy
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3. CASE STUDY: A NEW PATIENT WITH A HEPATITIS C RISK FACTOR
Michelle is a fit and active woman aged 49 years who recently
transferred to your practice because her previous GP retired.
In your initial consultation, you take a medical history, including
Michelle’s current medications. She has asthma and mild
gastric reflux. Her current medications include budesonide/
formoterol fumarate dihydrate 200/6 two inhalations twice
daily, salbutamol as required and methadone 40 mg daily.
You start a conversation with Michelle about her methadone
treatment. She reports that she injected heroin between the
ages of 14 and 35 years. She commenced methadone
treatment when she was 35 and has not injected drugs for the
past 10 years. She has no current or past history of significant
alcohol use. You ask if she has ever been tested for hepatitis C
and she reports that a previous GP told her she had been
exposed to the virus but she is unsure if she has a current
infection. She has not previously received antiviral therapy.
You order a comprehensive set of pathology investigations.
The results show that Michelle has current hepatitis C with
elevated aspartate aminotransferase (AST) and alanine
aminotransferase levels (Table).
You calculate Michelle’s AST to platelet ratio index (APRI)
score using her AST and platelet levels:
APRI = [(53/40)/255] x 100 = 0.52.
An APRI of 0.52 indicates a low likelihood of cirrhosis. Michelle
has evidence of past cleared hepatitis B virus (HBV) infection but
is not currently coinfected with HBV or HIV. She has normal renal
function and has not been previously treated for hepatitis C.
You decide that it is appropriate for Michelle to receive antiviral
treatment in primary care.
Treatment and monitoring will be covered in the next article
in this series.

TABLE. MICHELLE’S TEST RESULTS
Test

Result (reference range)

AST (U/L)

53 (<40)

ALT (U/L)

60 (<40)

Bilirubin (mcmol/L)

20 (4 to 20)

Platelets (x 10 cells/L)

255 (150 to 400)

eGFR (mL/min/1.7 m2)

97 (>90)

HCV RNA

Viral load 3,100,000 IU/mL,
genotype 3

Hepatitis B serology

Anti-HBs and anti-HBc positive,
HBsAg negative

HIV

Negative

Hepatitis A total antibody

Negative

Pregnancy test

Negative

Full blood count, urea and
electrolytes, INR, fasting
glucose level, body mass index

Within reference range

9

Abbreviations: ALT = alanine aminotransferase; anti-HBc = hepatitis B core
antibody; anti-HBs = hepatitis B surface antibody; AST = aspartate
aminotransferase; eGFR = estimated glomerular filtration rate; HBsAg = hepatitis B
surface antigen; HCV = hepatitis C virus; INR = international normalised ratio.
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4. PATIENT CIRCUMSTANCES THAT
REQUIRE REFERRAL TO A SPECIALIST2

5. RESOURCES ON HEPATITIS C MANAGEMENT FOR HEALTHCARE PROVIDERS
AND PATIENTS

Liver related

Gastroenterological Society of Australia (GESA)
Hepatitis C treatment resources for medical practitioners (www.gesa.org.au/
resources/hepatitis-c-treatment/):
• Consensus statement: Australian recommendations for the management of hepatitis C
virus infection (September 2018)
• Wallchart for GPs: Clinical guidance for treating hepatitis C virus infection: a summary
(also at: http://cart.gesa.org.au/membes/files/Resources/Hepatitis%20C/GP_
algorithm_Sep_Oct_edit2018.pdf); this summarises the clinical guidance for
treating hepatitis C, including a pre-treatment assessment form
• Request form: Remote consultation request for initiation of hepatitis C treatment
• Video: A practical guide to prescribing the new hepatitis C antiviral drugs in general practice

• Persistently abnormal liver function
test results after treatment
Coinfections and comorbidities
• HCV-HIV coinfection
• HCV-HBV coinfection
• Complex comorbidities
• Renal impairment (eGFR less than
50 mL/min/1.73 m2)
Treatment related
• Failed first-line DAA therapy
• Complex drug-drug interactions
• Experienced major adverse events
during treatment
Abbreviations: DAA = direct-acting antiviral;
HBV = hepatitis B virus; HCV = hepatitis C virus;
eGFR = estimated glomerular filtration rate.

This may include initiating opioid substitution therapy before starting treatment and referral to support services as
required.
More intensive adherence support may
need to be organised before treatment.
This will be covered in more detail in the
next article in the series.

Conclusion
The role of GPs in managing patients
with hepatitis C and preparing them
for DAA treatment is crucial to the
hepatitis C elimination effort in

Australia. Resources on hepatitis C
management for healthcare providers
and patients are shown in Box 5. If left
untreated, people with hepatitis C will
be at increased risk of developing
cirrhosis and associated complications,
including liver failure and hepatocellular carcinoma. Preparation for hepatitis
C treatment involves a few straight
forward steps. Most people diagnosed
with hepatitis C can be assessed and
treated in primary care, giving GPs an
exciting opportunity to offer their
patients a cure.   MT

Hepatitis Australia
A range of hepatitis C resources and information (www.hepatitisaustralia.com/Pages/
Category/hepatitis-c)
Eliminate Hepatitis C (EC) Partnership
Resources for primary care providers:
• EC Practice Support Toolkit (https://ecpartnership.org.au/toolkit): includes
resources to promote hepatitis C testing, treatment and follow up developed
specifically for GPs and other primary care providers
• Other resources (https://ecpartnership.org.au/resources)
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)
• Links to hepatitis C training, information and resources (www.ashm.org.au/HCV)
• REACH-C checklist (www.reach-c.ashm.org.au)
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